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The presence of axillary nodal metastases has a significant impact on locoregional and systemic treatment
decisions. Historically, all node-positive patients underwent complete axillary lymph node dissection; however, this
paradigm has changed over the last 10 years. The use of sentinel lymph node dissection has expanded from its
initial role as a surgical staging procedure in clinically node-negative patients. Clinically node-negative patients
with small volume disease found on sentinel lymph node dissection now commonly avoid more extensive axillary
surgery. There is interest in expanding this role to node-positive patients who receive neoadjuvant chemotherapy
as a way to restage the axilla in hopes of sparing women who convert to node-negative status from the morbidity
of complete nodal clearance. While sentinel lymph node dissection alone may not accomplish this goal, there
are novel techniques, such as targeted axillary dissection, that may now allow for reliable nodal staging after
chemotherapy.
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The presence of axillary lymph node metastases is the
most significant prognostic predictor in breast cancer,
and is often used to guide locoregional as well as sys-
temic therapy decisions [1–3]. The surgical management
of the axilla has undergone many changes with the
development of effective systemic therapy and improve-
ment in diagnostic tools. Many recent trials have
resulted in national conversation about optimal nodal
management with respect to diagnosis and therapy
[4–10]. In clinically node-negative patients undergoing
surgery as the first component of their breast cancer
treatment, sentinel lymph node dissection (SLND) is the
standard surgical approach to axillary staging. Multiple
studies have demonstrated that a sentinel lymph node
(SLN) can be identified in 93–99 % of patients with a
false negative rate (FNR; i.e., number of patients in
whom no cancer is seen in the SLN but metastases are
identified in other axillary nodes divided by the total
number of node positive patients) of 5–11 % [11, 12]. If
the SLN is negative for metastases, then no further* Correspondence: hkuerer@mdanderson.org
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creativecommons.org/publicdomain/zero/1.0/axillary surgery is required and the remaining lymph
nodes can be left in place. While historically patients
with a positive SLN underwent axillary lymph node dis-
section (ALND), this paradigm has changed in the last
10 years.Clinically node-negative patients with limited pathologic
node-positive disease
Several phase III, multicenter trials showing that ALND
can be omitted in selected SLN-positive women have re-
cently been reported with resulting changes in clinical
practice [4–6, 13]. These are summarized in Table 1.
The American College of Surgeons Oncology Group
(ACOSOG) Z0011 trial was a multi-institutional, pro-
spective non-inferiority trial [4, 14] which enrolled clin-
ically node-negative patients with T1 or T2 tumors
treated with breast conservation therapy (BCT) and ad-
juvant radiotherapy and were found to have one or two
positive SLNs. Patients were randomized to completion
ALND versus SLN alone and followed for evidence of
disease recurrence and for overall survival. There were
no differences in 5-year overall survival (91.9 % in
ALND vs. 92.5 % in SLND alone, P = 0.24) or disease-
free survival (82.2 % vs. 83.8 %, P = 0.13). In patientscess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Clinical trials evaluating axillary lymph node dissection in clinically node-negative patients. Summary of trials evaluating the
role of axillary lymph node dissection in patients presenting with no clinical evidence of axillary lymphadenopathy








ACOSOG Z0011 [4, 14] BCT 1-2 ALND 420 1.6 % 91.9 %
No ALND a 436 3.1 % 92.5 %
AMAROS [5] BCT or Mastectomy No limit ALND 744 Axillary recurrence 0.43 % 93.3 %
Axillary RT 682 1.19 % 92.5 %
IBCSG 23-01 [6] BCT or Mastectomy No limit- all metastases had
to be ≤2 mm
ALND 464 2.4 % 97.6 %
No ALND a 467 2.8 % 97.5 %
aNo axillary RT allowed
BCT, Breast conservation therapy; ALND, Axillary lymph node dissection; RT, Radiotherapy
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identified in the axillary specimen in 27 % of cases. The
investigators concluded that ALND could be safely omit-
ted in clinically node-negative patients with T1 or T2 tu-
mors undergoing BCT with one or two positive lymph
nodes. The majority of patients in this trial had post-
operative adjuvant whole-breast radiotherapy and sys-
temic therapy without specific directed nodal radiotherapy
to the axilla [15] (Fig. 1).
A similar European trial, the EORTC 10981-22023
AMAROS (After Mapping of the Axilla, Radiotherapy or
Surgery?) trial, was also a multi-institutional trial enrol-
ling clinically node-negative patients with positive SLNs
[5]. The trial started with eligibility criteria of a unifocal
tumor <3 cm, which was later expanded to include tu-
mors up to 5 cm and those with multifocal disease.
Similar to ACOSOG Z0011, a positive SLN wasFig. 1 Schema for the ACOSOG Z0011 Trial [4, 14]. The ACOSOG Z0011 tria
survival or locoregional recurrence in early breast cancer with one or two p
dissection versus those that had no further axillary therapyconsidered positive by standard hematoxylin and eosin
staining with isolated tumor cells considered negative.
They randomized 744 patients to ALND and 681 pa-
tients to axillary radiotherapy. Unlike the Z0011 trial,
the type of breast surgery was not dictated by the proto-
col, so patients undergoing mastectomy were eligible for
enrollment (17 % of the ALND cohort and 18 % of the
axillary radiotherapy group). In the ALND group, 33 %
(220/672) had additional positive non-SLNs identified.
They reported a 5-year axillary recurrence rate of 0.43 %
after ALND and 1.19 % in the axillary radiotherapy
group. The study was underpowered to show statistical
assurance of non-inferiority due to the low number of
events. Because patients were enrolled and randomized
before surgery, the trial included results on 3131 SLN-
negative patients with a 0.72 % 5-year axillary recurrence
rate. There were no differences in 5-year disease-freel was designed to determine whether there was a difference in overall
ositive sentinel lymph nodes who underwent axillary lymph node
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P = 0.18) or 5-year overall survival (93.3 % in ALND vs.
92.5 % in radiotherapy, P = 0.34). They also reported that
clinical evidence of lymphedema was higher in the
ALND group at 5 years (23 % compared to 11 %,
P <0.0001) as well as the proportion of patients with a
≥10 % increase in arm circumference (13 % vs. 6 %,
P = 0.0009). Interestingly, despite these changes, there
were no differences in quality of life scores.
The last trial that has led to a change in practice from
ALND to limited surgery with SLND is the International
Breast Cancer Study Group (IBCSG) 23-01 trial [6]. This
phase 3 non-inferiority trial randomized clinically T1/2,
N0 patients with micrometastases identified in SLNs to
ALND versus no further surgery. The trial did not
mandate any specific breast procedure so it included pa-
tients who underwent mastectomy and BCT and could
have any number of positive SLNs as long as all metasta-
ses were ≤2 mm [14]. This trial varies from the previous
ones in that a significant proportion of patients received
no radiotherapy or partial breast radiotherapy that
would not have incorporated the nodal region. Only 9 %
of patients in each group underwent mastectomy and
none received adjuvant radiation. In the remaining 91 %
of patients who underwent BCT, 19 % of both groups re-
ceived intra-operative radiotherapy alone, 70 % received
standard adjuvant whole breast radiation therapy, and 9
% of the ALND group and 8 % of the no ALND group
received a combination of intra-operative and whole
breast radiation therapy, while 2–3 % of the groups did
not receive any radiotherapy. Possibly reflecting the fact
that only patients with micrometastases were eligible for
enrollment, only 13 % of patients in the ALND group
had additional positive non-SLNs. Locoregional recur-
rences were similar in the two groups – 2.4 % (11/464)
of the ALND group versus 2.8 % (13/467) of patients
without ALND. Further, 5-year disease-free survival was
84.4 % in the ALND cohort compared to 87.8 % in the
group without ALND (P = 0.16).
While each of these three trials had different study de-
signs and eligibility criteria, they all reflect the same no-
tion that patients with clinically occult nodal metastases
found by SLND can safely avoid completion ALND with
equivalent oncologic outcomes.
Timing of SLND in patients undergoing neoadjuvant
chemotherapy
Neoadjuvant chemotherapy (NCT) is increasingly used in
node-negative breast cancer patients with the goal of
downsizing the tumor, which may facilitate BCT. The pre-
operative administration of chemotherapy allows for as-
sessment of in situ tumor response, thus identifying
agents with no efficacy early so that the patients can be
spared unnecessary toxicity. In addition, completepathologic response (pCR) is now recognized as a surro-
gate for long term outcomes, which has made the neoad-
juvant approach a valuable research platform [16, 17].
Another benefit of NCT is that 40–75 % of patients pre-
senting with clinically occult or biopsy proved-positive
lymph nodes will convert to pathologic lymph node-
negative when the nodes are removed at surgery [18–20].
Thus, SLND can lead to different results (and resulting
adjuvant therapies) depending on whether it is performed
before or after NCT. Advocates for performing upfront
SLND before initiating chemotherapy contend that SLN
identification is more successful before chemotherapy and
that complete nodal staging is important to treatment
planning [21]. However, this approach commits all
women, even if the SLN is negative, to two surgical proce-
dures. Furthermore, it commits women with clinically oc-
cult nodal disease to ALND even though the nodal
metastases would have been easily eradicated with chemo-
therapy. In addition, performing SLND after NCT reveals
the nodal status after NCT, which is a better prognostic
indicator than the identification of occult nodal metastases
pre-NCT [22]. In one study from the MD Anderson Can-
cer Center, the SLN identification rate was not altered by
the order of therapy (98.7 % if surgery first vs. 97.4 % if
SLN performed after NCT) with similar FNRs (4.1 % in
surgery first cohort vs. 5.8 % in NCT) [23]. After stratifica-
tion for tumor size, the probability of discovering positive
SLNs was lower if performed after NCT as opposed to be-
fore chemotherapy, which resulted in fewer patients re-
quiring ALND.
Patients presenting with clinically node-positive disease
The role of SLND in patients who present with clinically
involved and biopsy proven lymph nodes and have a
clinical response to NCT is currently under review.
Since 40–75 % of patients have eradication of their nodal
disease [18, 20, 24, 25], there is considerable interest in
finding reliable methods to restage the axilla in hope of
sparing a significant percentage of patients from the
morbidity of ALND. There are concerns, however, that
SLND may not be accurate in this setting – single insti-
tution reports have shown unacceptably high FNRs of
15–30 % [26–29]. The ACOSOG Z1071 trial was de-
signed to test the hypothesis that SLND performed with
a standardized surgical approach would accurately assess
nodal response after chemotherapy. The study enrolled
women with clinical T0-4 N1-2 M0 breast cancer with
nodal metastases confirmed by needle biopsy. After
completing neoadjuvant chemotherapy, enrolled patients
underwent SLND followed by completion ALND in
order to assess the FNR (Fig. 2). The study was designed
with a prespecified 10 % success threshold for FNR in
these patients. The overall nodal conversion rate was
41.1 %, but the trial confirmed previous reports that
Fig. 2 ACOSOG Z1071 Trial [7]. The ACOSOG Z1071 trial was
designed to test the reliability of sentinel lymph node dissection to
restage the axillary lymph nodes after neoadjuvant chemotherapy in
patients presenting with clinically positive lymph nodes
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the probability of nodal conversion [24]. While only
21.1 % (67/317) of patients with hormone-positive disease
achieved a nodal pCR, 49.4 % (84/170) of patients with
triple negative disease and 64.7 % (134 /207) of those with
HER2 amplified disease had nodal conversion.
SLNs were detected in 92.9 % of patients. In multivari-
ate analysis, only the use of a single tracer instead of
dual tracers increased the likelihood of not finding a
SLN (OR, 3.82; 95% CI, 1.47–9.92). Clinical T or N
stage, patient age, body mass index, or duration ofchemotherapy did not influence the ability to find at
least one SLN [30]. In 525 cN1 patients who had at least
two SLNs excised, the reported FNR was 12.6 % (90 %
CI, 9.85–16.05 %). One finding from the trial was that
surgical technique was crucial to SLND accuracy in this
setting. In contrast to the available literature from clinic-
ally node-negative patients that suggests that use of a
single tracer is acceptable [31, 32], the Z1071 trial had
very different results. The FNR rate improved dramatic-
ally from 20.3 % (95 % CI, 11–32.8 %) when a single
tracer was used to 10.8 % (95 % CI, 7.2–15.3 %) with the
use of dual tracers (P = 0.05). They also showed that the
FNR improved with the number of SLNs removed from
31 % (17/54) when only one node was removed, to 21 %
(19/90) when two nodes were removed, and to 9.1 %
(20/220) when three or more nodes were removed [7].
Since publishing of the trial primary endpoints, the au-
thors have further scrutinized the data for insights into
patient populations or technical aspects which could im-
prove the accuracy of SLND in predicting nodal conver-
sion. Central review of post-chemotherapy ultrasounds
was performed in 611 patients to determine if ultrason-
ography could predict nodal response. An abnormal
ultrasound after NCT was reasonably reliable – 71.8 %
of those patients did indeed have positive nodes on sur-
gical pathology. However, an ultrasound that showed
normal-appearing nodes was less accurate, as 56.5 %
of those patients actually had residual nodal disease.
The authors suggest that the use of ultrasound in this
setting might not accurately stage the axilla alone, but
might serve as a complement to SLND. If SLND had
only been performed on trial participants who had a
normal appearing ultrasound after chemotherapy, the
FNR would be 9.8 % [8].
The more comprehensive SENTINA (SENTinel Neo-
Adjuvant) study was designed to evaluate the optimal
timing of SLND in patients receiving NCT [9]. There
were four arms in the trial: (A) clinically node-negative
patients who underwent SLND before NCT, a portion of
whom were then moved to arm (B) if they had a positive
SLN, and then had a second SLND after NCT. The third
arm (C) consisted of clinically node-positive patients
who converted to clinically negative after NCT and then
underwent SLND to restage the axilla followed by
ALND. The remaining arm (D) consisted of clinically
node-positive patients who remained clinically positive
after NCT and underwent ALND (Fig. 3). In contrast to
the ACOSOG Z1071 trial, patients in the SENTINA
study did not have nodal metastases confirmed by nee-
dle biopsy. The authors showed that SLNs could be de-
tected in 99.1 % before NCT (Arm A); however, among
patients who had nodal metastases identified by a SLND
prior to NCT, a second SLND procedure (Arm B) was
only successful in 60.8 % demonstrating that patients
Fig. 3 SENTINA Trial [9]. The SENTINA trial was designed to evaluate the relationship of sentinel lymph node dissection in patients who received
neoadjuvant chemotherapy; the study arms are depicted below
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Arm C focused on the possibility of accurately restaging
the axillary nodes after NCT in clinically node-positive
patients. The authors report an overall FNR for SLND in
these patients of 14.2 %, with findings similar to the
Z1071 trial that the FNR was lower when more SLNs
were retrieved and dual tracers were used. Of note, one
important aspect of the trial is that they did not require
pathologic confirmation of lymph node involvement.
The FNR for SLND in the 149 patients who had biopsy-
confirmed metastases was 19 % compared to 12.3 % in
the 443 patients who were classified as node-positive
without pathologic confirmation.
Finally, the sentinel node biopsy following neoadju-
vant chemotherapy Canadian multi-institutional study
(SN FNAC) of patients with needle biopsy-proven
node-positive breast cancer [10], including 153 patients,
reported that the accuracy of SLND could be improved
with the use of immunohistochemistry (IHC). In theirtrial, if macrometastases (>2 mm) were considered positive
and micrometastases or isolated tumor cells were consid-
ered negative, the FNR would be 13.3 % (11/83) and was
decreased to 8.4 % (7/83) if micrometastases and isolated
tumor cells were considered positive. This study also
showed that the use of dual tracers and the retrieval of two
or more SLNs were crucial to improving accuracy. The in-
vestigators did an unplanned interim analysis after the
ACOSOG Z1071 results were released. Given the similarity
in their results and because of slow accrual, they made the
decision to close the trial before meeting their target ac-
crual. The ACOSOG Z1071 authors have also looked at
the contribution of IHC to improve SLND accuracy. While
the trial defined metastases as those seen on standard
hematoxylin and eosin staining, IHC was available on 470
patients. Using the IHC results, an additional 17 patients
were found to have positive SLNs, which improved the
FNR to 8.7 % (95 % CI, 5.6–11.8) [33]. The results of these
trials are summarized in Table 2.
Table 2 Clinical trials evaluating the accuracy of sentinel lymph node dissection in clinically node-positive patients. Summary of
trials designed to evaluate the accuracy of sentinel lymph node dissection to assess axillary nodal response to therapy in clinically
node-positive patients who receive neoadjuvant chemotherapy
Trial ACOSOG Z1071 [7, 33] SENTINA (Arm C) [9] SN FNAC [10]
Nodal eligibility criteria cN1-2 cN1-2 cN1-2
Endpoints reported for cN1 a
Biopsy required to confirm metastases? Yes No Yes
Number of patients cN1 = 603 592 153
cN2 = 34
Overall FNR (No IHC) 12.6 % a 14.2 % 13.4 %
FNR with IHC 8.7 % a Not reported 8.4 %
FNR depending on mapping agents
One agent 20.3 % 16 % 16 %
Dual agents 10.8 % 8.6 % 5.2 %
FNR by number of SLNs
One SLN 31 % 24.3 % 18.2 %
Two SLNs 21.1 % 18.5 % ≥2 SLNs = 4.9 %
Three or more SLNs 9.1 % 4.9 %
aLimited to patients classified as cN1 with ≥2 sentinel lymph nodes removed
FNR, False negative rate; IHC, Immunohistochemistry; SLN, Sentinel lymph node
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olds, there has been considerable national debate about
how to move forward in these efforts to accurately iden-
tify women who might safely avoid ALND after chemo-
therapy. One aspect being explored is actually based on
a very logical principle – perhaps the best lymph node
to evaluate after chemotherapy in order to determine re-
sponse is the node that had confirmed metastases before
therapy, i.e., the biopsied node. In the ACOSOG Z1071
trial, 170 patients had a clip placed in the biopsied node
similar to the way breast primary tumor sites are marked
after biopsy. In 107 patients in whom the SLN retrieved
was also documented to be the biopsy-proved clipped
node the FNR improved to 6.8 % (95 % CI, 1.9–16.5).
The clipped node was identified as a part of the
remaining axillary contents in 34 patients and was not
identified in 29 patients [33].
Development of novel procedures to increase accuracy
and target nodal disease after NCT
The intuitive concept that the best node to evaluate re-
sponse after NCT is the individual node that had been
proved to contain metastases by needle biopsy at diag-
nosis before NCT has been explored at MD Anderson
Cancer Center and at the Netherlands Cancer Institute
[34, 35]. In 2011, MD Anderson investigators established
a prospective registry study enrolling patients with
biopsy-confirmed nodal metastases with a clip placed in
the biopsied lymph node. The trial was designed to test
the hypotheses that the pathologic changes in the
clipped node with metastases accurately reflect theresponse to therapy in other nodes. This data was re-
cently presented at the Society of Surgical Oncologists
Annual meeting [34], and publication of this data is an-
ticipated soon. Preliminary data shows that specific
evaluation of the clipped node with documented metas-
tases before NCT in addition to SLND lowers the FNR
over SLND alone. In 25 % of cases evaluated, the clipped
node could not be identified as a sentinel node using
dual mapping agents or palpation. That is, if the SLND
procedure was performed alone, the node that had been
proven to have metastases prior to NCT would have
been left in the patient and not tested in a quarter of
cases. While this data is encouraging with respect to in-
creasing the accuracy of identifying residual disease, the
problem remained whether a clipped node could be se-
lectively localized and removed intra-operatively. This
challenge was answered with the development of tar-
geted axillary dissection (TAD) [36], which involves re-
moval of the node with known metastases (containing
the clip) in addition to removal of the nodes most likely
to harbor disease (the SLNs). Similar to the techniques
for breast tumor localization [37, 38], an I125 seed is
placed in the clipped node under ultrasound guidance
1–5 days before surgery, followed by radioisotope injec-
tion either preoperatively or intra-operatively. At the
time of surgery, the surgeon uses a gamma probe to
identify the node containing the clip and the seed, and
removes it. The surgeon proceeds to remove any other
blue nodes and uses the gamma probe on the techne-
tium settings to identify any remaining sentinel nodes.
The seed has been successfully retrieved in all cases to
Caudle and Kuerer BMC Medicine  (2015) 13:149 Page 7 of 9date and does not interfere with SLND. Given the low
FNR when this approach is used, it may be reasonable to
consider TAD for staging of the axilla after NCT in se-
lected patients with plans to omit ALND if no residual
disease is identified.
The initial results of the Netherland Cancer Institute
Marking Axillary Lymph Nodes with Radioactive Iodine
procedure in 100 patients with needle biopsy-proven
metastases for axillary staging after NCT was also re-
cently published [35]. A radioactive seed is placed as the
time of the initial biopsy if metastases are confirmed and
left in place through NCT. At surgery, the surgeon uses
a gamma probe to excise the node to assess response. In
this study, the radioactive node was identified in 97 %
and all patients underwent completion dissection to de-
termine the FNR, which was found to be 7 %. This was
a stand-alone procedure with completion ALND and no
lymphatic mapping or SLND was attempted in this
study. The authors also concluded that the procedure
might be useful in tailoring axillary therapy among pa-
tients who present with nodal metastases. Leaving the
radioactive seed in place for 3–6 months during NCT
would not likely to be feasible in the USA. Marking of
the nodes with documented metastases using India ink
at diagnosis has also been proposed [39], but many sur-
geons are concerned that this might require more dis-
section of healthy lymphatics to identify and retrieve
these nodes after NCT compared with more targeted
methods. Efforts are now underway to identify alterna-
tive approaches to localize nodes with proven metastases
using novel localizing methods.
Ongoing and upcoming clinical trials addressing axillary
disease management
NSABP-51/RTOG 1304 trial
With the acknowledgement that selected clinically node-
positive patients who have a response to NCT may not
undergo ALND in the future, cooperative groups are or-
ganizing trials to evaluate the optimal locoregional treat-
ment for patients. One such trial, NSABP-51/RTOG
1304, is currently enrolling patients with biopsy-proven
node-positive (N1) disease who undergo NCT and have
no residual nodal disease (by SLND or ALND), and ran-
domizes them to axillary radiation versus no axillary ra-
diation. The primary endpoints will be recurrence and
survival, but information on toxicity, effect of radiation
on cosmetic outcome, and quality of life will also be col-
lected [40].
ALLIANCE trial A11202
Another cooperative group trial is enrolling patients
with biopsy-proven N1 disease who do not achieve a
nodal pCR with NCT [41]. The goal of the Alliance
A11202 trial is to compare the efficacy of ALND plusradiation to radiation alone clinically node-positive pa-
tients who remain node-positive at SLND after NCT.
The primary end points of the trial are locoregional re-
currence and survival; however, there is a strong correla-
tive component of the trial dedicated to lymphedema
that should help delineate the differences in toxicity be-
tween axillary surgery and radiation together versus ra-
diation alone.
MD Anderson Trial 2013-0877
If it is feasible to identify abnormal axillary nodes and
prove metastases by percutaneous needle-biopsy before
NCT, might it be possible to do this after NCT and po-
tentially spare patients from any axillary nodal surgery?
This concept and hypothesis is being tested in MD An-
derson trial 2013-0877, which is designed as a study to
correlate fine needle aspiration to surgical excision to as-
sess for eradication of nodal metastases after NCT in
breast cancer.
Conclusions
The evaluation and management of axillary lymph nodes
is critical in breast cancer with impact on locoregional
as well as survival outcomes. ALND can be extremely
morbid for patients and adversely impact quality of life.
While ALND has historically been the standard ap-
proach to patients with nodal metastases, emerging data
has identified patients at low risk for regional recurrence
who may be spared the morbidity of this procedure in
the setting of appropriate multidisciplinary care. The
omission of ALND in clinically node-negative patients
with nodal metastases discovered by SLND has been in-
corporated broadly into clinical practice, although it is
unclear if the inclusion of axillary radiotherapy adds sub-
stantial benefit. The ability of SLND to accurately iden-
tify patients with a nodal pCR after NCT is still being
evaluated with the recognition that technical aspects are
crucial to the reliability of the test. Targeted axillary dis-
section, or SLND in addition to specific removal of the
sampled node (containing a clip), may be a way forward
in accurately restaging the axilla, thus identifying women
who do not benefit from completion ALND even among
patients who present with biopsy-proven nodal metasta-
ses. Moving forward, the safety and efficacy of selective
omission of ALND among patients who convert from
biopsy-proven node-positive breast cancer to pathologic
negative disease after NCT must be systematically stud-
ied. It is anticipated that systemic agents for breast can-
cer will further advance and the future holds the
potential for even elimination of axillary surgery in pa-
tients with node-positive breast cancer after NCT by in-
corporating improved imaging modalities with or
without percutaneous sampling of tissues for eradication
of disease.
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